P09.4

Clinical Causes: Genetic mutations in the CFTR gene, which are responsible for cystic fibrosis. Variations in the proteins involved in chloride transport across cell membranes, leading to abnormal sweat chloride tests. False-positive screening results due to factors such as prenatal medications or other medical conditions in the newborn. Laboratory errors during the screening process.

Key Symptoms: Elevated levels of chloride in sweat tests. Unusual or thickened mucus in the lungs and digestive tract observed during later assessments. Signs of poor weight gain and growth in infants. Persistent respiratory infections. Frequent, greasy, and bulky stools indicating digestive issues. Signs of intestinal blockage or meconium ileus in newborns.

Diagnosis Path: The diagnosis of cystic fibrosis following abnormal neonatal screening involves confirmatory testing. These may include: - Sweat chloride test, which measures the amount of salt in sweat. - Genetic testing to identify mutations in the CFTR gene. - Pancreatic function tests to assess digestive enzyme levels. Medical practitioners monitor symptoms and laboratory results to establish an accurate diagnosis and determine the severity of the condition.

Treatment Protocols: While no cure exists for cystic fibrosis, early management can greatly improve quality of life and longevity. Treatment strategies typically include: - Chest physiotherapy to loosen mucus in the lungs. - Medications such as bronchodilators, antibiotics, and mucus thinners. - Enzyme supplements to aid digestion. - Nutritional support to ensure adequate growth. - Regular monitoring and treatment of respiratory infections. - In some cases, newer therapies targeting the underlying genetic defect may be considered. Early detection through neonatal screening allows healthcare providers to initiate these treatments promptly, reducing complications and promoting better health outcomes.